You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
普萊柯(603566.SH):賽威生物擬以增資方式收購賽威生物及普泰生物100%股權
格隆匯 12-03 19:56

格隆匯12月3日丨普萊柯(603566.SH)公佈,公司參股公司中科基因擬以增資的方式收購洛陽賽威生物科技有限公司(以下簡稱“賽威生物”)和洛陽普泰生物技術有限公司(以下簡稱“普泰生物”)100%股權,增資金額為2100萬元,其中公司增資400萬元,關聯方餘江縣匯澤投資管理中心(有限合夥)(以下簡稱“餘江匯澤”)增資1200萬元,公司與關聯方共同投資構成關聯交易。收購完成後,賽威生物及普泰生物成為中科基因全資子公司,賽威生物及普泰生物的原股東相應轉為持有中科基因的股權。

賽威生物經營範圍包括生物醫藥材料的研發、生產、銷售及技術轉讓、技術諮詢、技術服務。普泰生物經營範圍包括動物疾病和人獸共患疾病用診斷試劑、檢測試劑、監測試劑、食品安全檢測試劑(不含危險化學品、易製毒品)的研究、生產、銷售(憑有效許可證經營)和與其相關的技術諮詢、技術服務、技術轉讓;儀器儀表及配件的生產及銷售。

本次交易系參股公司中科基因大股東為實現其所控制的企業之間的業務協同而進行的業務重組,重組後能夠更好的完善中科基因業務體系,同時也符合公司整體利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account